Tumor–stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma

被引:0
作者
Dong Wang
Jia Luo
YiMing Tao
机构
[1] The Affiliated Hospital of Qingdao University,Department of Liver Disease Center
[2] Central South University,Department of General Surgery, Xiangya Hospital
[3] Hunan Cancer Hospital,Department of Hepatobiliary Surgery
来源
BMC Cancer | / 23卷
关键词
Tumor stroma ratio; PD-L1; Hepatocellular carcinoma; Tumor microenvironment; Prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 117 条
[1]  
Rumgay H(2022)Global burden of primary liver cancer in 2020 and predictions to 2040 J Hepatol 77 1598-1606
[2]  
Arnold M(2017)Liver cancer cell of origin, molecular class, and effects on patient prognosis Gastroenterology 152 745-761
[3]  
Ferlay J(2015)The role of hepatic resection in the treatment of hepatocellular cancer Hepatology 62 440-451
[4]  
Sia D(2010)The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma Med Oncol 27 255-261
[5]  
Villanueva A(2015)Challenges to liver transplantation and strategies to improve outcomes Gastroenterology 148 307-323
[6]  
Friedman SL(2011)Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study Hepatology 53 136-147
[7]  
Llovet JM(2018)CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage Transl Oncol 11 552-558
[8]  
Roayaie S(2015)Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis Ann Surg 261 947-955
[9]  
Jibara G(2018)Tumour-stroma ratio and prognosis in gastric adenocarcinoma Br J Cancer 119 435-439
[10]  
Tabrizian P(2022)Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer BMC Cancer 22 1082-1135